SCHEMBL21425523

SCHEMBL21425523

Cc1nc(NC(=O)N2CCC(C)(C)C2=O)ccc1Oc1ccnc(NC(=O)N2CCN(C)CC2)c1

nearest known ligand 0.68

Predicted protein targets (top 8)

geneUniProtsupporting neighboursconfidence
▸ CSF1R P07333 19/20 0.68
▸ PDGFRA P16234 13/20 0.68
▸ KIT P10721 4/20 0.68
▸ MET P08581 2/20 0.46
▸ PDGFRB P09619 7/20 0.45
▸ CYP2C9 P11712 1/20 0.43
▸ KDR P35968 1/20 0.42
▸ FLT3 P36888 2/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL21425524 0.90 CSF1R (0.66) CSF1RPDGFRAKITMETPDGFRB
SCHEMBL21425516 0.90 CSF1R (0.70) CSF1RPDGFRAKITMETPDGFRB
SCHEMBL21425677 0.89 CSF1R (0.71) CSF1RPDGFRAKITMETPDGFRB
SCHEMBL30890842 0.89 CSF1R (0.71) CSF1RPDGFRAKITMETPDGFRB
SCHEMBL21425522 0.87 CSF1R (0.67) CSF1RPDGFRAKITMETPDGFRB
SCHEMBL27117089 0.86 CSF1R (0.68) CSF1RPDGFRAKITMETPDGFRB
SCHEMBL21785874 0.83 CSF1R (0.48) CSF1RPDGFRAKITMETPDGFRB
SCHEMBL21772046 0.83 CSF1R (0.78) CSF1RPDGFRAKITMETPDGFRB
SCHEMBL21425517 0.83 CSF1R (0.68) CSF1RPDGFRAKITMETPDGFRB
SCHEMBL16036512 0.81 CSF1R (0.45) CSF1RPDGFRAKITMETPDGFRB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3632907-B1 N-(AZAARYL)CYCLOLACTAM-1-CARBOXAMIDE DERIVATIVE, PREPARATION METHOD THEREFOR, AND USE THEREOF ABBISKO THERAPEUTICS CO LTD (CN) 2024-02-28 — — EP disclosed
EP-3632907-B1 N-(AZAARYL)CYCLOLACTAM-1-CARBOXAMIDE DERIVATIVE, PREPARATION METHOD THEREFOR, AND USE THEREOF ABBISKO THERAPEUTICS CO LTD (CN) 2024-02-28 — — EP disclosed
US-11149021-B2 N-(azaaryl)cyclolactam-1-carboxamide derivative, preparation method therefor, and use thereof ABBISKO THERAPEUTICS CO., LTD. (CN) 2021-10-19 — — US disclosed
US-11149021-B2 N-(azaaryl)cyclolactam-1-carboxamide derivative, preparation method therefor, and use thereof ABBISKO THERAPEUTICS CO., LTD. (CN) 2021-10-19 — — US disclosed
EP-3632907-A1 N-(AZAARYL)CYCLOLACTAM-1-CARBOXAMIDE DERIVATIVE, PREPARATION METHOD THEREFOR, AND USE THEREOF Abbisko Therapeutics Co., Ltd. (CN) 2020-04-08 — — EP disclosed
EP-3632907-A1 N-(AZAARYL)CYCLOLACTAM-1-CARBOXAMIDE DERIVATIVE, PREPARATION METHOD THEREFOR, AND USE THEREOF Abbisko Therapeutics Co., Ltd. (CN) 2020-04-08 — — EP disclosed
US-20200071302-A1 N-(AZAARYL)CYCLOLACTAM-1-CARBOXAMIDE DERIVATIVE, PREPARATION METHOD THEREFOR, AND USE THEREOF ABBISKO THERAPEUTICS CO., LTD. (CN) 2020-03-05 — — US disclosed
US-20200071302-A1 N-(AZAARYL)CYCLOLACTAM-1-CARBOXAMIDE DERIVATIVE, PREPARATION METHOD THEREFOR, AND USE THEREOF ABBISKO THERAPEUTICS CO., LTD. (CN) 2020-03-05 — — US disclosed
WO-2018214867-A9 N-(AZAARYL)CYCLOLACTAM-1-CARBOXAMIDE DERIVATIVE, PREPARATION METHOD THEREFOR, AND USE THEREOF 上海和誉生物医药科技有限公司 2019-10-03 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20200071302-A1 N-(AZAARYL)CYCLOLACTAM-1-CARBOXAMIDE DERIVATIVE, PREPARATION METHOD THEREFOR, AND USE THEREOF CSF1R, CSF3R, FAR1 CSF1R 1/4885PDGFRA 586/4885KIT 195/4885
US-11149021-B2 N-(azaaryl)cyclolactam-1-carboxamide derivative, preparation method therefor, and use thereof CSF1R, CSF3R, FAR1 CSF1R 1/4885PDGFRA 586/4885KIT 195/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback